Trial Profile

A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Feladilimab (Primary) ; GSK 1795091 (Primary) ; GSK 3174998 (Primary) ; Pembrolizumab
Indications Head and neck cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors GlaxoSmithKline; GSK

Most Recent Events

30 Mar 2022 Status changed from active, no longer recruiting to completed.
16 Jul 2021 Planned End Date changed from 25 Jan 2022 to 11 Mar 2022.
24 Jul 2020 Status changed from suspended to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com